Reversal of multidrug resistance by B859-35, a metabolite of B859-35, niguldipine, verapamil and nitrendipine
- 1 May 1992
- journal article
- Published by Springer Nature in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 118 (5) , 361-366
- https://doi.org/10.1007/bf01294440
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- B-859-35, a new drug with anti-tumor activity reverses multi-drug resistanceInternational Journal of Cancer, 1991
- Retention of vital dyes correlates inversely with the multidrug-resistant phenotype of adriamycin-selected murine fibrosarcoma variantsExperimental Cell Research, 1990
- Expression of mdr1 and mdr3 Multidrug-resistance Genes in Human Acute and Chronic Leukemias and Association With Stimulation of Drug Accumulation by CyclosporineJNCI Journal of the National Cancer Institute, 1990
- Reversal of multi‐drug resistance in human KB cell lines by structural analogs of verapamilInternational Journal of Cancer, 1990
- Enhancement of adriamycin® cytotoxicity in a multidrug resistant Chinese hamster ovary (CHO) subline, CHO-Adrr, by toremifene and its modulation by alpha1 acid glycoproteinMaterials, 1990
- DNA topoisomerase dysfunction: A new goal for antitumor chemotherapyBioEssays, 1990
- Stereoselective inhibition of thromboxane‐induced coronary vasoconstriction by 1,4‐dihydropyridine calcium channel antagonistsChirality, 1990
- Multidrug Resistance During Chemical Carcinogenesis: A Mechanism Revealed?JNCI Journal of the National Cancer Institute, 1988
- Daunomycin accumulation in resistant tumor cells as a screening model for resistance modifying drugs: Role of protein bindingCancer Letters, 1987
- Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodiesNature, 1985